GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (FRA:3XI) » Definitions » Minority Interest

Biomind Labs (FRA:3XI) Minority Interest : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Biomind Labs's minority interest for the quarter that ended in Sep. 2023 was €0.00 Mil.


Biomind Labs Minority Interest Historical Data

The historical data trend for Biomind Labs's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Minority Interest Chart

Biomind Labs Annual Data
Trend Dec21 Dec22
Minority Interest
- -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomind Labs Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Biomind Labs (FRA:3XI) Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (FRA:3XI) Headlines

No Headlines